The Dollars And Sense Of Antitrust Class Certification: Part 2

Law360 (September 11, 2020, 4:04 PM EDT) -- Welcome back to "The Dollars and Sense of Antitrust Class Certification," a series discussing significant legal and economic issues arising in antitrust class certification cases.

Our earlier Law360 guest article analyzed the legal standards for class certification in pharmaceutical antitrust cases and the economic theories used to support or oppose certification in recent cases. This installment will again focus predominantly on decisions in the pharmaceutical industry. 

We begin with a brief recap of recent class certification decisions around the country. We then partner with economists to take a closer examination of an important decision from the U.S. Court of Appeals for the Third Circuit,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!